Sign in
LIMN Stock Price, Chart, Stats & News
Liminatus Pharma, Inc. Class A Common Stock
Save
3.19M
Market cap
–
Current P/E
–
Forward P/E
LIMN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.12% |
ROA | -192.09% |
ROE | 39.18% |
D/E | -0.88x |
Interest coverage ratio | -10.74x |
LIMN valuation
P/E | – |
P/S | – |
P/B | -3.08x |
P/CF | -0.49x |
P/FCF | -0.48x |
P/OCF | -0.49x |
PEG | -2.70x |
EV multiple | -1.83x |
About
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer.
Similar securities
Based on sector and market capitalization
Report issue